DUSTIN DEEMER: Open Payments
NPI 1558549592 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$492 in 17 payments from 11 companies in 2025. Trend: 2023 $1,053 · 2024 $72 · 2025 $492
Food & beverage: $492
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 4 | $227 |
| Novo Nordisk Inc | 2 | $44 |
| PFIZER INC. | 2 | $38 |
| Amgen Inc. | 2 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| CeQur Corporation | 1 | $23 |
| BETA BIONICS, INC. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
Products named: Dexcom G6 Transmitter, ELIQUIS, OTEZLA, Kerendia, CAPLYTA, Rybelsus, CeQur Simplicity, iLet Bionic Pancreas.
Industry payments across TX — which companies pay providers there.
